Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes.

ABSTRACT:

Objective

To determine variables associated with glycemic and body weight responses when adding exenatide to basal insulin-treated type 2 diabetes.

Research design and methods

Exploratory subgroup analyses based on baseline A1C, disease duration, and BMI of a 30-week study comparing exenatide twice daily to placebo, added to optimized insulin glargine (intent-to-treat analysis: 137 exenatide; 122 placebo).

Results

Exenatide participants had greater A1C reductions compared with optimized insulin glargine alone, irrespective of baseline A1C (P < 0.001). Exenatide participants with longer diabetes duration and those with lower BMI had greater A1C reductions (P < 0.01). Exenatide participants lost more weight, regardless of baseline A1C or BMI (P < 0.05). Exenatide partic

SUBMITTER: Rosenstock J 

PROVIDER: S-EPMC3329851 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature